I Went Looking for the Future of Innovation. I Found Robots Making Medicine
At the Strange Summit in San Francisco, founders and investors shared how AI, robotics, and fusion are solving real-world problems and scaling up.
Aggregator
Gamma Had 100 Million Users. Its CEO Decided It Was Time to Reinvent the Product
Most founders pivot when they’re failing. Here is why Grant Lee threw out what was working to survive the next era of software.
Private Assets Are Coming to Your Portfolio… Be Ready
Motley Fool contributors Tyler Crowe, Lou Whiteman, and Jon Quast discuss:
Apple’s Foldable iPhone Duo Arrives in Stores: Smartphone Review
The first-generation Apple foldable may feel awkward, but it’s an intriguing step toward merging phones and tablets into one.
Why Has This Teenager Tracked Down 11,377 Moths Since April?
Violet Clinton is doing award-winning entomological field research. Her dad still has to buy the beer for her moth bait.
Rogers (RCI) Q3 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo
Sugar Prices Continue to Sag From Last Week’s Contract High
March NY world sugar #11 (SBH27 ) closed down -0.32 (-1.56%) on Thursday, and December London ICE white sugar #5 (SWZ26 ) closed down -9.80 (-1.80%). March NY world sugar prices fell to a 2-week low on Thursday on continued long liquidation pressure after posting a contract high last Wednesday....
Sugar Prices Continue to Sag From Last Week’s Contract High
March NY world sugar #11 (SBH27 ) closed down -0.32 (-1.56%) on Thursday, and December London ICE white sugar #5 (SWZ26 ) closed down -9.80 (-1.80%). March NY world sugar prices fell to a 2-week low on Thursday on continued long liquidation pressure after posting a contract high last Wednesday....
Stocks See Continued Downward Pressure from AI Anxiety and Oil Prices
The S&P 500 Index ($SPX ) (SPY ) is down -0.45%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.08%. December E-mini S&P futures (ESZ26 ) are down -0.43%, and December E-mini Nasdaq futures (NQZ26...
Brilliant Acquisition Corp Announces T3 Defense Inc. Regained Compliance with Nasdaq Stockholders' Equity Requirement of $10,000,000
Brilliant Acquisition Corp, filing as T3 Defense Inc., announced that it has regained compliance with Nasdaq's Stockholders' Equity Requirement. On August 20, 2026, the company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market, LLC no
Brilliant Acquisition Corp Announces T3 Defense Inc. Regained Compliance with Nasdaq Stockholders' Equity Requirement of $10,000,000
Brilliant Acquisition Corp, filing as T3 Defense Inc., announced that it has regained compliance with Nasdaq's Stockholders' Equity Requirement. On August 20, 2026, the company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market, LLC no
Russia and Ukraine agree to local ceasefire in Oleshky amid deepening humanitarian crisis
People in Russian-occupied city facing severe shortages of food, water and electricity, with some reportedly surviving on weeds
The White House has said that Russia and Ukraine have agreed to a ceasefire in the Russian-occupied city of Oleshky, where a deepening humanitarian crisis has left thousands of civilians struggling to survive.
In a statement on Friday, the White House said both sides had agreed to halt all military operations in the city from 27 October to allow humanitarian aid deliveries and preparations for the evacuation of civilians.
Continue reading...Accendra Health Consensus Price Target Decreased by 16.53% to $1.29
The average one-year price target for Accendra Health (NYSE:ACH) (DB:6OM) has been revised to $1.29 / share. This is a decrease of 16.53% from the prior estimate of $1.54 dated September 29, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not con
Accendra Health Consensus Price Target Decreased by 16.53% to $1.29
The average one-year price target for Accendra Health (NYSE:ACH) (DB:6OM) has been revised to $1.29 / share. This is a decrease of 16.53% from the prior estimate of $1.54 dated September 29, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not con
Genmab A/S Announces Positive Topline Results from Phase 3 RAINFOL-02 Trial
Genmab A/S announced positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with pl
Genmab A/S Announces Positive Topline Results from Phase 3 RAINFOL-02 Trial
Genmab A/S announced positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with pl
Four fraternity pledges arrested on hazing allegations after teen forced into truck: cops
Four Phi Delta Theta pledges at Texas State University were arrested on misdemeanor hazing charges after an 18-year-old was allegedly forced into a truck.
Four fraternity pledges arrested on hazing allegations after teen forced into truck: cops
Four Phi Delta Theta pledges at Texas State University were arrested on misdemeanor hazing charges after an 18-year-old was allegedly forced into a truck.
The AI Rout: Sorting CAPEX Fact From Fiction
Despite the brutal pullbacks in AI-related stocks, debt fears are far overblown and the bullish fundamental case remains rock-solid for the foreseeable future.
The AI Rout: Sorting CAPEX Fact From Fiction
Despite the brutal pullbacks in AI-related stocks, debt fears are far overblown and the bullish fundamental case remains rock-solid for the foreseeable future.